Key figures

Third quarter, July 1 – September 30, 2025

(figures in parentheses refer to the corresponding period in the previous year)

  • Net sales amounted to 0 (0).
  • Other operating income amounted to 1,201 (1,662) thousand SEK.
  • Operating profit (EBIT) amounted to -10,389 (10,937) thousand SEK.
  • Profit after tax amounted to -10,389 (-10,937) thousand SEK.
  • Earnings per share before and after dilution: -0.86 (-1.55) SEK.
  • Cash flow from operating activities was -12,640 (-9,176) thousand SEK.

 

Significant events during the quarter

  • Scale-up of cartridge manufacturing at FlexMedical Solutions.
  • Strong interest in the Psyros POC system at the international WHX Labs congress.
  • Positive results reported for traumatic brain injury (TBI) biomarkers in collaboration with BRAINBox Solutions, confirming broad platform potential.

 

Significant events after the end of the period

  • Selected as semi-finalist in the ADLM 2026 Disruptive Technology Award Competition.
  • Secures second patent in Japan for the Psyros technology.
  • Design freeze achieved for the Psyros instrument.